ZVRA
Zevra Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | +5 | 28.98M | $414.85M | +11 | −6 |
| Q1 2026 | 69 | 0 | 26.10M | $242.75M | +4 | −4 |
| Q4 2025 | 68 | +1 | 25.36M | $227.23M | +1 | n/a |
| Q3 2025 | 16 | +2 | 19.14M | $181.99M | +2 | n/a |
| Q2 2025 | 11 | 0 | 17.09M | $150.53M | n/a | n/a |
| Q1 2025 | 8 | 0 | 6.58M | $49.25M | +1 | −1 |
| Q4 2024 | 8 | +1 | 6.30M | $52.58M | +2 | −1 |
| Q3 2024 | 6 | +2 | 1.92M | $13.36M | +3 | −1 |
| Q2 2024 | 4 | n/a | 1.15M | $5.62M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.04M | +14.2% | $7.25M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Adage Capital Partners ✦ | 649.00K | New | $4.50M | 0.0% | New | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 97.89K | New | $679,329 | 0.0% | New | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 67.91K | -35.5% | $471,288 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 52.08K | New | $361,415 | 0.0% | New | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 13.60K | 0.0% | $95,000 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $4.50M | 0.0% |
| Millennium Management | $679,329 | 0.0% |
| Marshall Wace | $361,415 | 0.0% |
Exited
| Renaissance Technologies | $552,720 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 147 holders, 40.93M shares, $378.34M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 20.00K sh · $224,948
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology